WAM
HRTX icon

Wealthspire Advisors (Maryland)’s Heron Therapeutics HRTX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,618
Closed -$40K – 1139
2019
Q1 		$40K Buy
1,618
+1,119
+224% +$29.3K ﹤0.01% 971
2018
Q4 		$13K Buy
+499
New +$13.7K ﹤0.01% 1371

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s HRTX Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 1,618 shares — an estimated $40K sold.

Wealthspire Advisors (Maryland) first reported a position in HRTX in Q4 2018 and held it in 2 quarters. The position peaked at $40K in Q1 2019. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 1,618 Heron Therapeutics shares in Q2 2019, an estimated $40K.
  • Wealthspire Advisors (Maryland) first reported a position in Heron Therapeutics in Q4 2018 and held it in 2 quarters.
  • Wealthspire Advisors (Maryland)'s Heron Therapeutics position peaked at $40K in Q1 2019.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.